Meeting
2023 ASCO Annual Meeting
Utilizing predictive modeling to identify patients at high-risk of death from immune checkpoint inhibitor therapy-related pneumonitis.
Authors
Antonious Ziad Hazim
Mayo Clinic, Rochester, MN
Antonious Ziad Hazim , Jacob Tyler Shreve , Irene Riestra Guiance , Gordon Ruan , John McGlothlin , Keith Mcconn , Robert Haemmerle , Konstantinos Leventakos , Ashley Egan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Care Delivery and Regulatory Policy
Track
Care Delivery and Quality Care
Sub Track
Clinical Informatics/Advanced Algorithms/Machine Learning
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1552)
DOI
10.1200/JCO.2023.41.16_suppl.1552
Abstract #
1552
Poster Bd #
146
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Beyond CPS for PD-L1 scoring: Genetic alterations that impact efficacy of immunotherapy in hepatocellular carcinoma (HCC).
First Author: Emil Lou
Poster
2020 ASCO Virtual Scientific Program
Impact of SWI/SNF complex mutations in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors: Immuno-oncology biomarker study in LC-SCRUM-Japan (LC-SCRUM-IBIS).
First Author: Kiyotaka Yoh
Poster
2018 ASCO Annual Meeting
Immuno-oncology biomarker study in a large cohort of LC-SCRUM-Japan: Assessment of PD-L1 expression and tumor mutation burden in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
First Author: Kiyotaka Yoh
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Benefit of immune checkpoint inhibitors (ICI) for patients with advanced esophageal squamous cell carcinoma and low PD-L1 expression: A systematic review and meta-analysis.
First Author: Mario Machado Lopes